Macrogenics Inc Stock Price, News & Analysis

MacroGenics, Inc. (Nasdaq: MGNX) will release its first quarter 2021 financial results on April 29, 2021, after market close. A conference call is scheduled for the same day at 4:30 pm ET to discuss the results and corporate developments. Interested parties can join the call by dialing (877) 303-6253 for domestic or (973) 409-9610 for international access, using Conference ID# 5257004. The call will also be available via a listen-only webcast on the company's Investor Relations website, with a recorded replay accessible for 30 days.

MacroGenics, Inc. (Nasdaq: MGNX) announced its participation at the AACR Annual Meeting from April 10-15, 2021, showcasing three innovative antibody-based therapeutic technologies. The highlighted therapeutic candidates include MGC018, which showed potent antitumor activity in mouse models, currently under Phase 1 trials for advanced solid tumors, margetuximab, designed to enhance immune responses, and IMGC936, directed against ADAM9-expressing tumors. The presentations signal MacroGenics' commitment to advancing its oncology pipeline.

MacroGenics, focused on innovative monoclonal antibody therapies for cancer, will participate in several investor conferences in March 2021. Key events include:

• Cowen 41^st Annual Health Care Conference on March 2, where management will join the Breast Cancer Panel at 2:10 pm ET.
• H.C. Wainwright & Co. Global Life Sciences Conference on March 9 for one-on-one meetings and an on-demand corporate overview.
• Barclays Global Healthcare Conference on March 11 for one-on-one meetings and an overview at 3:45 pm ET.

Webcasts will be accessible on their Investor Relations website.

MacroGenics, Inc. (NASDAQ: MGNX) has announced the upcoming commercial launch of its first FDA-approved drug, MARGENZA, expected in March 2021. The approval was granted for treating HER2-positive breast cancer in patients with prior anti-HER2 treatments. The company reported a revenue increase to $104.9 million for 2020, up from $64.2 million in 2019, alongside a reduced net loss of $129.7 million compared to $151.8 million the previous year. Key clinical trials, including those for flotetuzumab and margetuximab, are set to advance in 2021, with multiple updates anticipated throughout the year.

MacroGenics, Inc. (Nasdaq: MGNX) announced it will release its financial results for Q4 and full year 2020 on February 25, 2021, after market close. A conference call to discuss the results and corporate progress will occur the same day at 4:30 PM ET. Interested parties can join by calling (877) 303-6253 domestically or (973) 409-9610 internationally, using Conference ID 6094343. A listen-only webcast will be available on the company’s Investor Relations page and accessible for 30 days post-call.

MacroGenics, Inc. (Nasdaq: MGNX) announced the appointment of Federica O’Brien to its Board of Directors. With 25 years of financial and operational experience, O’Brien will also join the Audit Committee, bringing insights from her roles at various biopharmaceutical and medical device companies. CEO Scott Koenig expressed confidence in her ability to guide the company as it prepares to launch its first product and enhance its cancer treatment options.

MacroGenics (Nasdaq: MGNX) announced a $10 million milestone related to the development of retifanlimab under its global collaboration with Incyte. The FDA has accepted Incyte's BLA for retifanlimab, targeting a PDUFA action date of July 25, 2021, for treating advanced squamous carcinoma of the anal canal. Incyte is conducting Phase 3 trials of retifanlimab for non-small cell lung cancer and other cancers. MacroGenics has received $65 million in milestones, with potential total milestones of $355 million and commercial royalties ranging from 15% to 24% on net sales.

MacroGenics, a biopharmaceutical company focused on monoclonal antibody therapies for cancer, will participate in two investor conferences in February 2021. The first is the Guggenheim Healthcare Talks 2021 Oncology Day on February 11 at 11:30 AM ET, followed by the SVB Leerink 10th Annual Global Healthcare Conference on February 24 at 12:00 PM ET. Both events will be held virtually, and presentations can be accessed under the 'Events & Presentations' section on the MacroGenics website. Archived replays will be available for 30 days post-conference.

MacroGenics, Inc. (Nasdaq: MGNX) announced successful results from the Phase 3 SOPHIA trial for MARGENZA (margetuximab-cmkb), showing a 24% reduction in disease progression compared to Herceptin (trastuzumab) in metastatic HER2-positive breast cancer patients. This therapy is approved in the U.S. for patients with advanced disease who have undergone multiple prior treatments. The median progression-free survival (PFS) was 5.8 months for MARGENZA versus 4.9 months for Herceptin. The company plans to commercialize MARGENZA in March 2021.